IL-2-话题@MedSci

#IL-2#

62篇内容 | 3109人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1626045, encodeId=8ac91626045ce, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验, objectType=article, longId=166678, objectId=b3b81666e8fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3b81666e8fb, replyNumber=0, likeNumber=94, createdTime=2019-05-25, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3b81666e8fb, moduleTitle=礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3b81666e8fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626044, encodeId=829c16260447a, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=EBioMedicine：IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关, objectType=article, longId=166433, objectId=55eb166433ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55eb166433ae, replyNumber=0, likeNumber=108, createdTime=2019-05-22, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55eb166433ae, moduleTitle=EBioMedicine：IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55eb166433ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626043, encodeId=e07c162604331, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, objectType=article, longId=161542, objectId=b41f1615426c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b41f1615426c, replyNumber=0, likeNumber=99, createdTime=2019-03-03, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b41f1615426c, moduleTitle=欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b41f1615426c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626042, encodeId=ae091626042e8, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Ann Rheum Dis：系统性硬化症中循环滤泡辅助T细胞增多并通过IL-21通路促进浆母细胞分化, objectType=article, longId=160152, objectId=b8e4160152a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8e4160152a1, replyNumber=0, likeNumber=68, createdTime=2019-02-18, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8e4160152a1, moduleTitle=Ann Rheum Dis：系统性硬化症中循环滤泡辅助T细胞增多并通过IL-21通路促进浆母细胞分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8e4160152a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626041, encodeId=ee80162604104, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Nature：创新IL-2模拟蛋白，有望成为癌症免疫疗法新武器, objectType=article, longId=158036, objectId=37ea1580364f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37ea1580364f, replyNumber=0, likeNumber=71, createdTime=2019-01-16, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37ea1580364f, moduleTitle=Nature：创新IL-2模拟蛋白，有望成为癌症免疫疗法新武器, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37ea1580364f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626040, encodeId=f3011626040e3, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Sci Rep：IL-33、IL-25和TSLP能够导致真菌相关的蛋白酶诱导的先天性气道炎症的发展, objectType=article, longId=157106, objectId=58a115e106e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58a115e106e5, replyNumber=0, likeNumber=63, createdTime=2019-01-02, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58a115e106e5, moduleTitle=Sci Rep：IL-33、IL-25和TSLP能够导致真菌相关的蛋白酶诱导的先天性气道炎症的发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58a115e106e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626039, encodeId=1a541626039fa, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Int Arch Allergy Immunol：鼻腔内给药IL-27能够减轻鼻过敏性响应和症状, objectType=article, longId=156125, objectId=d12115612563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d12115612563, replyNumber=0, likeNumber=69, createdTime=2018-12-19, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d12115612563, moduleTitle=Int Arch Allergy Immunol：鼻腔内给药IL-27能够减轻鼻过敏性响应和症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d12115612563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626038, encodeId=6bd01626038b8, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, objectType=article, longId=149686, objectId=d1891496860a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1891496860a, replyNumber=0, likeNumber=135, createdTime=2018-09-28, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1891496860a, moduleTitle=MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1891496860a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626037, encodeId=6d06162603e82, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, objectType=article, longId=149073, objectId=52291490e33c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52291490e33c, replyNumber=0, likeNumber=44, createdTime=2018-09-20, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52291490e33c, moduleTitle=III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=52291490e33c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626036, encodeId=b79e162603620, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, objectType=article, longId=148645, objectId=6dae148645a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dae148645a9, replyNumber=0, likeNumber=64, createdTime=2018-09-13, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dae148645a9, moduleTitle=Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6dae148645a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626035, encodeId=42b516260354f, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=GUT：携带IL-23受体的TNFR2 + T细胞的扩增与克罗恩病中抗TNF治疗的分子抗性相关, objectType=article, longId=140647, objectId=4e9114064e97, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e9114064e97, replyNumber=0, likeNumber=82, createdTime=2018-06-14, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e9114064e97, moduleTitle=GUT：携带IL-23受体的TNFR2 + T细胞的扩增与克罗恩病中抗TNF治疗的分子抗性相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e9114064e97)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626034, encodeId=51d71626034c6, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Blood：B细胞在体外对IL-21的反应或可作为IL2RG/JAK3缺陷 SCID患者进行异基因造血干细胞移植后体液免疫的生物标志物, objectType=article, longId=137448, objectId=21c913e448d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21c913e448d2, replyNumber=0, likeNumber=43, createdTime=2018-05-09, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21c913e448d2, moduleTitle=Blood：B细胞在体外对IL-21的反应或可作为IL2RG/JAK3缺陷 SCID患者进行异基因造血干细胞移植后体液免疫的生物标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21c913e448d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626033, encodeId=48b616260331a, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=SCI REP：血浆IL-23和IL-5作为肝泡状棘球蚴病患者病变代谢活性的替代标记物！, objectType=article, longId=132345, objectId=ad62132345b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad62132345b5, replyNumber=0, likeNumber=70, createdTime=2018-03-15, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad62132345b5, moduleTitle=SCI REP：血浆IL-23和IL-5作为肝泡状棘球蚴病患者病变代谢活性的替代标记物！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad62132345b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626032, encodeId=d974162603218, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Sci Signal：IL-2信号通路对自身免疫疾病的影响, objectType=article, longId=124851, objectId=2fbd12485119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fbd12485119, replyNumber=0, likeNumber=80, createdTime=2017-12-29, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fbd12485119, moduleTitle=Sci Signal：IL-2信号通路对自身免疫疾病的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fbd12485119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626031, encodeId=6c3616260313c, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Mediators Inflamm：IL-25参与了屋尘螨敏感的过敏性鼻炎的发展, objectType=article, longId=114893, objectId=e2e61148932c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2e61148932c, replyNumber=0, likeNumber=72, createdTime=2017-10-01, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2e61148932c, moduleTitle=Mediators Inflamm：IL-25参与了屋尘螨敏感的过敏性鼻炎的发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2e61148932c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626030, encodeId=b3f0162603093, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=NEJM：IL-12和IL-23阻断可以有效的缓解白细胞粘附缺陷1型症状, objectType=article, longId=93072, objectId=3850930e257, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3850930e257, replyNumber=0, likeNumber=69, createdTime=2017-03-25, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3850930e257, moduleTitle=NEJM：IL-12和IL-23阻断可以有效的缓解白细胞粘附缺陷1型症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3850930e257)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626029, encodeId=76bd162602917, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=J immunol: 树突状细胞分泌IL-27的新调节机制, objectType=article, longId=87313, objectId=552e8e31323, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=552e8e31323, replyNumber=0, likeNumber=78, createdTime=2017-01-13, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=552e8e31323, moduleTitle=J immunol: 树突状细胞分泌IL-27的新调节机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=552e8e31323)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626028, encodeId=9ded162602836, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=Nat Med：北大栗占国教授发现低剂量IL-2能治疗系统性红斑狼疮, objectType=article, longId=76010, objectId=abfde60100e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abfde60100e, replyNumber=0, likeNumber=49, createdTime=2016-08-29, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abfde60100e, moduleTitle=Nat Med：北大栗占国教授发现低剂量IL-2能治疗系统性红斑狼疮, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abfde60100e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626027, encodeId=26e1162602e0c, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=J immunol：IL-4, IL-21, 与IFN-γ共同调节激活B细胞T-bet基因表达, objectType=article, longId=73421, objectId=fb2fe3421a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb2fe3421a7, replyNumber=0, likeNumber=74, createdTime=2016-07-23, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb2fe3421a7, moduleTitle=J immunol：IL-4, IL-21, 与IFN-γ共同调节激活B细胞T-bet基因表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb2fe3421a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1626026, encodeId=91071626026ec, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, objectTitle=J immunol：真菌感染引发IL-27分泌负向调节T细胞活性, objectType=article, longId=70619, objectId=f532e061964, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f532e061964, replyNumber=0, likeNumber=135, createdTime=2016-06-14, rootId=0, userName=tomyang93, userId=ea8220955712, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f532e061964, moduleTitle=J immunol：真菌感染引发IL-27分泌负向调节T细胞活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f532e061964)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-2

2020-05-29

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

礼来IL-23抑制剂治疗克罗恩病2期结果积极，今年启动3期试验

2019-05-25

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

EBioMedicine：IL-2响应的减少与总lgE水平提高和过敏性鼻炎的加重相关

2019-05-22

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

欧洲CHMP对AbbVie的IL-23单抗Risankizumab治疗中度至重度斑块型银屑病作出积极评价

2019-03-03

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Ann Rheum Dis：系统性硬化症中循环滤泡辅助T细胞增多并通过IL-21通路促进浆母细胞分化

2019-02-18

heli0118 (审核中...)

前往app查看评论内容

#IL-2#

Nature：创新IL-2模拟蛋白，有望成为癌症免疫疗法新武器

2019-01-16

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Sci Rep：IL-33、IL-25和TSLP能够导致真菌相关的蛋白酶诱导的先天性气道炎症的发展

2019-01-02

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Int Arch Allergy Immunol：鼻腔内给药IL-27能够减轻鼻过敏性响应和症状

2018-12-19

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

MorphoSys宣布开始3期试验（PROTOSTAR）评估IL-23单抗Guselkumab对银屑病儿童患者的疗效

2018-09-28

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

III期试验证明IL-23单抗Tildrakizumab在3年内对中度-严重慢性斑块状银屑病患者维持良好疗效和安全性

2018-09-20

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Lilly将启动IXORA-R头对头试验：比较IL-17A单抗Taltz和IL-23单抗Tremfya治疗中度至重度斑块型银屑病患者的疗效

2018-09-13

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

GUT：携带IL-23受体的TNFR2 + T细胞的扩增与克罗恩病中抗TNF治疗的分子抗性相关

2018-06-14

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Blood：B细胞在体外对IL-21的反应或可作为IL2RG/JAK3缺陷 SCID患者进行异基因造血干细胞移植后体液免疫的生物标志物

2018-05-09

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

SCI REP：血浆IL-23和IL-5作为肝泡状棘球蚴病患者病变代谢活性的替代标记物！

2018-03-15

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Sci Signal：IL-2信号通路对自身免疫疾病的影响

2017-12-29

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Mediators Inflamm：IL-25参与了屋尘螨敏感的过敏性鼻炎的发展

2017-10-01

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

NEJM：IL-12和IL-23阻断可以有效的缓解白细胞粘附缺陷1型症状

2017-03-25

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

J immunol: 树突状细胞分泌IL-27的新调节机制

2017-01-13

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

Nat Med：北大栗占国教授发现低剂量IL-2能治疗系统性红斑狼疮

2016-08-29

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

J immunol：IL-4, IL-21, 与IFN-γ共同调节激活B细胞T-bet基因表达

2016-07-23

tomyang93 (审核中...)

前往app查看评论内容

#IL-2#

J immunol：真菌感染引发IL-27分泌负向调节T细胞活性

2016-06-14

科室
- - 订阅+
  - 更多科室
工具
服务